Señales en vivo de ENSC | Maximiza tus Ganancias con Getagraph.com

COMPRAR 107585 min ago

@ $0.897

Emitido: 14 feb 2024 @ 15:28

Retorno: -33.07%

Señal anterior: feb 14 - 10:42

Señal anterior: Vender

Retorno: -0.39 %

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 09:30):

Stats
Volumen de hoy	1 713.00
Volumen promedio	540 200
Capitalización de mercado	4.40M
EPS	$0 ( 2024-04-04 )
Próxima fecha de ganancias	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0100 (1.71%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-02	Gower Bob G	Buy	90 287	Common Stock
2023-03-01	Gower Bob G	Buy	270 000	Common Stock
2023-02-28	Gower Bob G	Buy	109 300	Common Stock
2022-12-09	Gower Bob G	Buy	357 143	Common Stock
2022-12-09	Gower Bob G	Buy	714 286	Warrants

INSIDER POWER
99.26
Last 80 transactions
Buy: 23 095 136 \| Sell: 3 675 006

Volumen Correlación

Largo: 0.13 (neutral)

Corto: 0.26 (neutral)

Signal:(46.493) Neutral

Ensysce Biosciences, Inc. Correlación

10 Correlaciones Más Positivas
SVAC	0.928
PAIC	0.905
PRVB	0.904
SVOK	0.878
ALR	0.862
TLGT	0.852
ALLR	0.847
LKCO	0.844
RDHL	0.843
ELEV	0.839

10 Correlaciones Más Negativas
NETE	-0.92
LWAC	-0.92
MDRRP	-0.916
SRAC	-0.904
WSBCP	-0.895
RAVN	-0.889
HNST	-0.889
OVBC	-0.886
MRBK	-0.885
MNSBP	-0.883

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ensysce Biosciences, Inc. Correlación - Moneda/Commodity

0.36
( neutral )

0.62
( weak )

0.00
( neutral )

-0.15
( neutral )

0.33
( neutral )

Ensysce Biosciences, Inc. Finanzas

Annual	2023
Ingresos:	$2.23M
Beneficio Bruto:	$-5.36M (-240.17 %)
EPS:	$-4.69

FY	2023
Ingresos:	$2.23M
Beneficio Bruto:	$-5.36M (-240.17 %)
EPS:	$-4.69

FY	2022
Ingresos:	$2.52M
Beneficio Bruto:	$-17.31M (-686.08 %)
EPS:	$-138.73

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-29.60

Financial Reports:

No articles found.

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.